September 27, 2005 -- Cell Therapeutics soared almost 50% higher on news that its lung cancer drug, Xyotax, was more effective among women than men. Using the statistic of the number of patients who were alive at the end of one year, the study shows that 36% of the women survived to that milestone, while just 25% of the men lived a full year. We look at the drug and its Phase II trial...
